Abstract

Factors Associated with Poor Quality of Life in a Canadian Cohort of Patients with Inflammatory Bowel Disease: A Cross-sectional Study

J Can Assoc Gastroenterol. 2020 May 16;4(2):91-96. doi: 10.1093/jcag/gwaa014.eCollection 2021 Apr.

Amir Nazarian 1, Kirles Bishay 1, Reza Gholami 1, Michael A Scaffidi 1, Rishad Khan 1, Daniel Cohen-Lyons 1, Nadia Griller 1, Joshua B Satchwell 1, Jeffrey P Baker 1, Samir C Grover 1 2, Elizabeth Jan Irvine 1

 
     

Author information

  • 1Division of Gastroenterology, St. Michael's Hospital, Toronto, Ontario, Canada.
  • 2Li Ka Shing Knowledge Institute, University of Toronto, Toronto, Ontario, Canada.

Abstract

Background: Health-related quality of life (QoL) is often adversely affected in patients with inflammatory bowel disease (IBD). We aimed to identify factors associated with poor QoL among Canadian patients with IBD in clinical remission.

Methods: We enrolled patients at a single academic tertiary care center with inactive IBD. All eligible patients completed a series of questionnaires that included questions on demographics, disease activity, anxiety, depression and the presence of irritable bowel syndrome (IBS) symptoms. Stool sample for fecal calprotectin (FC) was also collected to assess for subclinical inflammation. The primary outcome measure was QoL assessed by the short inflammatory bowel disease questionnaire (SIBDQ), with planned subgroup comparisons for fatigue, anxiety, depression and IBS symptoms.

Results: Ninety-three patients were eligible for inclusion in this study. The median SIBDQ scores were lower in patients with anxiety (P < 0.001), depression (P = 0.004), IBS symptoms (P < 0.001) and fatigue (P = 0.018). Elevated FC in patients in clinical remission did not impact QoL. These findings were consistent on multivariate linear regression.

Conclusions: Anxiety, depression, fatigue and IBS symptoms are all independently associated with lower QoL in patients with inactive IBD. Clinicians are encouraged to screen for these important factors as they may detrimentally impact QoL in IBD patients even in clinical remission.

© Copyright 2013-2021 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.